Karim I. Budhwani
Principal investigator, leads CerFlux, Inc..
MedtechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2020First federal award
$1.9MFederal grants as PI4 awards
2Patents grantedLatest Dec 5, 2023
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
4 awards · $1.9M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 31, 2026 | NSF | SBIR Phase II SBIR Phase II: Predictive Ex Vivo Solid Tumor New Approach Method (NAM) for Screening Anticancer Agents | $1.3M | CerFlux, Inc. |
| Jul 21, 2023 | NSF | SBIR Phase I SBIR Phase I: Predictive ex vivo solid tumor biopsy-chip multiplexer for screening anticancer agents | $275K | CerFlux, Inc. |
| May 24, 2021 | NIH | SBIR Phase I Development of personalized ex vivo predictive technology for rapidly matching patient tumors with chemotherapy regimens before treatment. | $52K | CerFlux, Inc. |
| Sep 10, 2020 | NIH | SBIR Phase I Development of personalized ex vivo predictive technology for rapidly matching patient tumors with chemotherapy regimens before treatment. | $301K | CerFlux, Inc. |
3 patents as inventor
- US 11097274CerFlux, Inc.Aug 24, 2021
- US 11833514CerFlux, Inc.Dec 5, 2023
- US CerFlux, Inc.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#1,278
Awards as PI#643
Patents#185
Companies
- CerFlux, Inc.Leads (SEC Form D) · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.